Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
Br J Clin Pharmacol
; 75(4): 919-30, 2013 Apr.
Article
em En
| MEDLINE
| ID: mdl-22882307
ABSTRACT
AIM:
To perform a systematic review and meta-analysis of published clinical trials to determine incidence rate and overall risk of hypertension with vandetanib in cancer patients.METHODS:
A comprehensive literature search for studies published up to March 2012 was performed. Summary incidence rates, relative risk (RR), and 95% confidence intervals (CI) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included trials.RESULTS:
A total of 11 trials with 3154 patients were included for the meta-analysis. The summary incidences of all-grade and high-grade hypertension in patients with cancer were 24.2% [95% confidence interval (CI), 18.1-30.2%] and 6.4% (95% CI, 3.3-9.5%), respectively. Subgroup analysis demonstrated that the pooled incidences of all-grade and high-grade hypertension were 21.8% [95% CI, 15-30.5%] and 7.6% (95% CI, 2.8-18.8%), respectively, among non-small-cell lung cancer (NSCLC) patients, and 32.1% (95% CI 27.3-37.3%) and 8.8% (5.9%-12.9%), respectively, among MTC patients, and 15.4 (95% CI 3.2-33.7%) and 3.4% (95% CI 1%-11.1%) respectively, among non-MTC/NSCLC tumors patients. Furthermore, vandetanib was associated with a significant increased risk of all-grade hypertension (RR 5.1, 95% CI 3.76-6.92, P = 0.000) and high-grade hypertension (RR 8.06, 95% CI 3.41-19.04, P = 0.000) in comparison with controls.CONCLUSIONS:
There is a significant risk of developing hypertension in cancer patients receiving vandetanib. Appropriate monitoring and treatment is strongly recommended to prevent cardiovascular complications.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Piperidinas
/
Quinazolinas
/
Hipertensão
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
/
Incidence_studies
/
Prognostic_studies
/
Risk_factors_studies
/
Systematic_reviews
Limite:
Humans
Idioma:
En
Revista:
Br J Clin Pharmacol
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
China